Literature DB >> 10458406

Expression of messenger RNAs for membrane-type 1, 2, and 3 matrix metalloproteinases in human renal cell carcinomas.

Y Kitagawa1, K Kunimi, T Uchibayashi, H Sato, M Namiki.   

Abstract

PURPOSE: Three different membrane-type matrix metalloproteinases (MT1, 2, and 3-MMP) that can activate proMMP-2 (progelatinase A) are thought to play an important role in invasion and metastasis by various human carcinomas. To further clarify this role, we examined mRNA expression of MT-MMPs in human renal cell carcinomas.
MATERIALS AND METHODS: mRNA was extracted from 25 clinical specimens of renal cell carcinoma and 23 specimens of normal renal parenchyma remote from the tumor. Reverse transcription polymerase chain reaction (RT-PCR) using specific primers was performed, and PCR products were hybridized to 32P-labeled internal probes and analyzed by a bioimage analyzer.
RESULTS: MT1, 2, and 3-MMP mRNA expression in carcinomas was significantly higher than in normal parenchyma. In terms of the pathologic stage, MT1-MMP mRNA expression in pT2 and pT3 tumors was significantly higher than those in pT1 tumors. Although the sample size was small, it was evident that MT3-MMP mRNA expression in clear cell subtype renal cell carcinomas was higher than in the group of tumors including the granular cell subtype.
CONCLUSIONS: These three MT-MMPs may play an important role in the pathogenesis of human renal cell carcinoma, and MT1-MMP in particular is important in invasion by carcinoma cells. It is interesting that the expression of MT3-MMP was higher in carcinomas, especially clear cell carcinoma, than in normal parenchyma, so that MT3-MMP may provide a clue an understanding of the molecular mechanism of carcinogenesis in human kidney.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10458406     DOI: 10.1097/00005392-199909010-00088

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  Variability in melanoma metalloproteinase expression profiling.

Authors:  Orsi Giricz; Janelle L Lauer; Gregg B Fields
Journal:  J Biomol Tech       Date:  2010-12

2.  Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.

Authors:  Brenda L Petrella; Jouko Lohi; Constance E Brinckerhoff
Journal:  Oncogene       Date:  2005-02-03       Impact factor: 9.867

3.  Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A).

Authors:  Joji Iida; Krista L Wilhelmson; Janet Ng; Peter Lee; Charlotte Morrison; Eric Tam; Christopher M Overall; James B McCarthy
Journal:  Biochem J       Date:  2007-05-01       Impact factor: 3.857

4.  Translocating a High-Affinity Designer TIMP-1 to the Cell Membrane for Total Renal Carcinoma Inhibition: Putting the Prion Protein to Good Use.

Authors:  Bingjie Jiang; Yuewei Xu; Yihe Zhang; Meng Huee Lee
Journal:  Mol Cell Biol       Date:  2019-08-27       Impact factor: 4.272

5.  Graded activation of the MEK1/MT1-MMP axis determines renal epithelial cell tumor phenotype.

Authors:  Rajeev Mahimkar; Maria Alejandra Alfonso-Jaume; Leslie M Cape; Rajvir Dahiya; David H Lovett
Journal:  Carcinogenesis       Date:  2011-09-28       Impact factor: 4.944

6.  MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer.

Authors:  X T Xu; Q Xu; J L Tong; M M Zhu; F Nie; X Chen; S D Xiao; Z H Ran
Journal:  Br J Cancer       Date:  2012-03-27       Impact factor: 7.640

7.  Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase.

Authors:  Brenda L Petrella; Constance E Brinckerhoff
Journal:  Mol Cancer       Date:  2006-12-01       Impact factor: 27.401

8.  Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma.

Authors:  Zhen-kui Qiao; Yan-long Li; Hong-tao Lu; Ke-liang Wang; Wan-hai Xu
Journal:  World J Surg Oncol       Date:  2013-01-03       Impact factor: 2.754

9.  The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including TGFB1 and MMP13.

Authors:  Pauline Hascoet; Franck Chesnel; Florence Jouan; Cathy Le Goff; Anne Couturier; Eric Darrigrand; Fabrice Mahe; Nathalie Rioux-Leclercq; Xavier Le Goff; Yannick Arlot-Bonnemains
Journal:  Oncotarget       Date:  2017-06-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.